Metagenomi Therapeutics, Inc.
MGX
$1.16
-$0.01-0.86%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.56M | 22.33M | 25.21M | 30.91M | 33.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.56M | 22.33M | 25.21M | 30.91M | 33.77M |
| Cost of Revenue | 88.60M | 88.59M | 94.43M | 96.10M | 97.07M |
| Gross Profit | -75.04M | -66.26M | -69.22M | -65.18M | -63.30M |
| SG&A Expenses | 25.53M | 26.52M | 26.79M | 27.09M | 28.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.13M | 115.11M | 121.22M | 123.18M | 125.58M |
| Operating Income | -100.57M | -92.78M | -96.01M | -92.27M | -91.81M |
| Income Before Tax | -93.65M | -86.03M | -87.93M | -90.04M | -90.29M |
| Income Tax Expenses | -190.00K | -146.00K | -58.00K | -1.30M | -3.17M |
| Earnings from Continuing Operations | -93.46 | -85.89 | -87.87 | -88.74 | -87.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -93.46M | -85.89M | -87.87M | -88.74M | -87.12M |
| EBIT | -100.57M | -92.78M | -96.01M | -92.27M | -91.81M |
| EBITDA | -95.40M | -87.55M | -90.70M | -86.79M | -86.30M |
| EPS Basic | -2.49 | -2.30 | -2.36 | -2.39 | -2.35 |
| Normalized Basic EPS | -1.56 | -1.42 | -1.45 | -1.37 | -1.35 |
| EPS Diluted | -2.49 | -2.30 | -2.36 | -2.39 | -2.35 |
| Normalized Diluted EPS | -1.56 | -1.42 | -1.45 | -1.37 | -1.35 |
| Average Basic Shares Outstanding | 150.06M | 149.56M | 149.00M | 148.83M | 148.25M |
| Average Diluted Shares Outstanding | 150.06M | 149.56M | 149.00M | 148.83M | 148.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |